Neuritis
8
1
1
1
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
12.5%
1 terminated out of 8 trials
50.0%
-36.5% vs benchmark
25%
2 trials in Phase 3/4
100%
1 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (8)
Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection
RESting-state Functional MRI in Patients With Optic Neuritis for ANticipation of reCovEry
Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation
National Vaccine Adverse Event Reporting Survey and Etiology
Role of PRF With MTA and Theracal After Pulpotomy in Relieving Pain
Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.
Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple Sclerosis
Study of TENS in Reducing Symptoms of Peripheral Neuropathy Induced by Chemotherapy